Nina Grenon Discusses the Impact of Early Palliative Care

The pathological complete response among patients who received durvalumab plus chemotherapy was 17.2% vs 4.3% in the placebo plus chemotherapy arm.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients.

In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.

The objective response rate with sacituzumab govitecan plus pembrolizumab was 56%.

Patrimumab deruxtecan garnered a 29.8% overall response rate in pretreated patients with EGFR-mutated non–small cell lung cancer.